Latest news with #RAPTOR™
Business Wire
06-08-2025
- Business
- Business Wire
Pleno Inc. Announces First Commercial Agreement with Slopes Bio, Inc.
SAN DIEGO--(BUSINESS WIRE)-- Pleno Inc., an early-stage biotechnology company developing innovative multi-omic solutions, and Slopes Bio, Inc., an innovative high-complexity accredited laboratory, today announced a comprehensive commercial agreement in biological target detection and personalized health. The agreement marks the official commercial launch of Pleno's RAPTOR™ instrument platform. This agreement with Slopes Bio helps bring to life our vision of AI-driven precision medicine at scale with RAPTOR. Share The two companies are collaborating closely on a pilot project to develop an extensible polygenic risk score panel for use in Slopes' laboratory with more than 400 patient samples processed. Clinical data demonstrated the improved accuracy, target plexity and economics of Pleno's proprietary Hypercoding™ technology when compared to existing solutions. A white paper with additional detail is to be published shortly. Under the terms of the agreement, Slopes Bio will purchase up to five RAPTOR instruments and corresponding consumables sufficient to process more than 100,000 samples annually. The first two instruments will be deployed in Slopes' Utah-based production lab beginning later this month. "This agreement with Slopes Bio helps bring to life our vision of AI-driven precision medicine at scale with RAPTOR," said Dr. Vik Vaz, CEO of Pleno. "An industry leader like Slopes Bio's deployment of multiple RAPTOR instruments in their production lab demonstrates both the commercial viability and the real-world scalability of our platform. Together, we're positioned to transform how the industry approaches high-throughput biological target detection." The finalized collaboration also extends beyond the current planned instrument deployment. Pleno and Slopes will jointly develop multiple high-sample-volume applications to meet increasing market demand for high plexity, efficient, scalable solutions in personalized health and wellness testing. "Pleno's RAPTOR technology aligns perfectly with our mission to empower health and wellness innovators with reliable, efficient laboratory services," said Justen Nadauld, CEO of Slopes Bio. "The performance improvements and cost efficiencies enabled by Hypercoding will allow us to scale our operations significantly while maintaining the quality standards our clients expect." The August 2025 deployment positions both companies to capitalize on the growing demand for high-throughput biological analysis in personalized medicine. About Pleno Inc. Pleno Inc. is a San Diego-based biotechnology company developing the RAPTOR™ multi-omic instrument platform to revolutionize biological target detection. Powered by proprietary Hypercoding™ technology, able to detect up to 10,000 targets per sample, RAPTOR simplifies complex multi-omic workflows and delivers unprecedented improvements in performance, cost, and scalability across applications including oncology, pharmacogenomics, genotyping, proteomics, and agrigenomics. For more information visit the website About Slopes Bio, Inc. Slopes Bio is a high-complexity, accredited laboratory that empowers health and wellness innovators with reliable, efficient, and actionable lab services. From custom assay development to end-to-end testing, kitting, and analytics, Slopes Bio brings personalized health solutions to life.
Yahoo
16-05-2025
- Business
- Yahoo
Liberate Bio Announces Presentation to Update on RAPTOR LNP Platform and CAR-M Therapeutic Programs
CAMBRIDGE, Mass., May 16, 2025--(BUSINESS WIRE)--Liberate Bio, Inc., a biotechnology company developing medicines which efficiently and selectively deliver payloads to immune cells while bypassing the live, announced an oral presentation by Melissa Deck - Director of Platform, demonstrating the success of Liberate's RAPTOR™ screening platform and NHP data for the company's first lead candidates at the Oligonucleotide and Peptide Therapeutics 2025 (TIDES) being held May 19th-22nd, 2025 in San Diego, California. "We built the RAPTOR platform to address key limitations of existing delivery vehicles and to expand the potential of oligonucleotide therapeutics beyond the liver. We are thrilled to have reached this critical inflection point," said Walter R. Strapps, Ph.D., Chief Scientific Officer of Liberate. "The presentation shows that our lead lipids robustly deliver mRNA cargo to monocytes and macrophages in non-human primates. This has enabled our first therapeutic program, in vivo CAR-M to treat solid tumors." Key Highlights from the Presentation: Liberate Bio has built RAPTOR™, a robust nanoparticle screening platform for evaluating and identifying extrahepatic delivery vehicles directly in non-human primates (NHPs). RAPTOR™ has generated lipid nanoparticles (LNPs) with significant delivery to bone marrow and expression of mRNA cargo in monocytes, macrophages and other cell-types relevant to in vivo CAR therapy. At the same time, Liberate's lead candidates show a five -old reduction in liver accumulation of cargo. TIDES Presentation Details: TITLE: "Innovating Nucleic Acid Delivery: RAPTOR, Artificial Intelligence, and the Future of CAR-M" SESSION TITLE: Delivery of Macromolecules PRESENTATION TYPE: Oral PRESENTER: Melissa K. Deck, Director of Platform, Liberate Bio. DATE AND TIME: Wednesday, 21 May, 10:45am PT About Liberate Bio Our vision at Liberate Bio is to achieve the extraordinary—delivering genetic medicines that transcend liver-based limitations, liberating patients from disease. Today's genetic medicines are limited by the availability of safe, effective delivery vehicles that direct nucleic acid therapeutics to any organ other than the liver. To realize the full potential of genetic medicines, we use our proprietary screening platform to rapidly evaluate rational and artificial intelligence-designed nanoparticles, reducing the cycle time for identifying novel vehicles from years to months. Our initial lead candidates are allowing us to pursue multiple therapeutic areas based on delivery to various bone marrow derived cells including HSCs, monocytes and macrophages. We have built the team and a suite of tools that allows us to rapidly move RNA therapeutics to the clinic by significantly increasing the translatability of the preclinical work. For more information about the company's technologies, team, and mission, visit View source version on Contacts Walter Strapps, CSOwstrapps@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
16-05-2025
- Business
- Business Wire
Liberate Bio Announces Presentation to Update on RAPTOR LNP Platform and CAR-M Therapeutic Programs
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Liberate Bio, Inc., a biotechnology company developing medicines which efficiently and selectively deliver payloads to immune cells while bypassing the live, announced an oral presentation by Melissa Deck - Director of Platform, demonstrating the success of Liberate's RAPTOR™ screening platform and NHP data for the company's first lead candidates at the Oligonucleotide and Peptide Therapeutics 2025 (TIDES) being held May 19th-22nd, 2025 in San Diego, California. 'We built the RAPTOR platform to address key limitations of existing delivery vehicles and to expand the potential of oligonucleotide therapeutics beyond the liver. We are thrilled to have reached this critical inflection point,' said Walter R. Strapps, Ph.D., Chief Scientific Officer of Liberate. 'The presentation shows that our lead lipids robustly deliver mRNA cargo to monocytes and macrophages in non-human primates. This has enabled our first therapeutic program, in vivo CAR-M to treat solid tumors.' Key Highlights from the Presentation: Liberate Bio has built RAPTOR™, a robust nanoparticle screening platform for evaluating and identifying extrahepatic delivery vehicles directly in non-human primates (NHPs). RAPTOR™ has generated lipid nanoparticles (LNPs) with significant delivery to bone marrow and expression of mRNA cargo in monocytes, macrophages and other cell-types relevant to in vivo CAR therapy. At the same time, Liberate's lead candidates show a five -old reduction in liver accumulation of cargo. TIDES Presentation Details: TITLE: 'Innovating Nucleic Acid Delivery: RAPTOR, Artificial Intelligence, and the Future of CAR-M' SESSION TITLE: Delivery of Macromolecules PRESENTATION TYPE: Oral PRESENTER: Melissa K. Deck, Director of Platform, Liberate Bio. About Liberate Bio Our vision at Liberate Bio is to achieve the extraordinary—delivering genetic medicines that transcend liver-based limitations, liberating patients from disease. Today's genetic medicines are limited by the availability of safe, effective delivery vehicles that direct nucleic acid therapeutics to any organ other than the liver. To realize the full potential of genetic medicines, we use our proprietary screening platform to rapidly evaluate rational and artificial intelligence-designed nanoparticles, reducing the cycle time for identifying novel vehicles from years to months. Our initial lead candidates are allowing us to pursue multiple therapeutic areas based on delivery to various bone marrow derived cells including HSCs, monocytes and macrophages. We have built the team and a suite of tools that allows us to rapidly move RNA therapeutics to the clinic by significantly increasing the translatability of the preclinical work. For more information about the company's technologies, team, and mission, visit
